20:54 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Aubagio and other DHODH inhibitors as epilepsy therapies

DISEASE CATEGORY: Neurology INDICATION: Epilepsy Patient sample, cell culture and mouse studies suggest inhibiting DHODH could help treat epilepsy. Metabolic modeling of transcriptome data from the cortex and hippocampus of epilepsy patients and two rat...
22:42 , May 15, 2019 |  BC Extra  |  Clinical News

May 15 Clinical Quick Takes: Principia, Agios, Y-mAbs, Pfizer

Principia gets $30M from Sanofi for Phase IIb MS trial start  Principia Biopharma Inc. (NASDAQ:PRNB) said partner Sanofi (Euronext:SAN; NASDAQ:SNY) began a Phase IIb trial of SAR442168 to treat relapsing multiple sclerosis, triggering a $30...
00:03 , May 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting S1PR1 for neuropathic pain

DISEASE CATEGORY: Neurology INDICATION: Pain Rat and mouse studies suggest S1PR1 inhibitors or modulators could help treat neuropathic pain. In a rat model of neuropathic pain, astrocyte-specific knockout of S1PR1 in the CNS or intrathecal...
23:45 , May 9, 2019 |  BC Extra  |  Company News

May 9 Company Quick Takes: Chimerix, Puma, Janssen

Chimerix abandons brincidofovir trials  Chimerix Inc. (NASDAQ:CMRX) will cut its workforce in half after deciding to discontinue all clinical trials of adenovirus candidate brincidofovir due to low patient recruitment, five years after access to the...
21:59 , Apr 25, 2019 |  BC Extra  |  Company News

Salix licenses S1P receptor modulator from Mitsubishi

Mitsubishi has found a new partner for its oral S1P receptor modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd. gained exclusive rights Thursday to develop...
23:16 , Apr 24, 2019 |  BC Extra  |  Company News

Biogen reiterates late-stage M&A priority as it calls off planned aducanumab trial

As it contemplates exiting β-amyloid programs, Biogen is prioritizing late-stage M&A to shore up its pipeline and preparing to deliver near-term Phase II readouts from a stable of other non-Alzheimer's disease candidates. The bellwether also...
21:27 , Apr 23, 2019 |  BC Extra  |  Politics & Policy

CMS increases tech add-on for CAR Ts as it sorts out new DRG code

As CMS continues to seek input on how best to reimburse hospitals for the ancillary costs of CAR Ts, the agency has said it will increase to $242,450 from $186,500 the maximum new technology add-on...
21:54 , Apr 22, 2019 |  BC Extra  |  Company News

Variant expands pipeline with InflamaCore inflammasome deal

InflamaCore granted Variant exclusive, worldwide rights to develop and commercialize IC 100 and related products to treat inflammatory diseases. Variant Pharmaceuticals Inc. (Weston, Fla.) also gained rights to develop companion diagnostics for the mAb targeting...
19:25 , Apr 19, 2019 |  BC Week In Review  |  Company News

Newer drugs lift Roche’s 1Q sales

Driven by newer drugs and expanded indications, Roche beat analyst expectations for its 1Q19 global pharmaceutical sales by 7% at CHF11.9 billion ($11.8 billion) vs. the Street's CHF11.2 billion ($11 billion) estimate. Pharmaceutical sales increased...
01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...